Polaryx Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Selling, General & Admin	1.58	1.54	1.01
Research & Development	6.06	2.81	2.77
Operating Expenses	7.63	4.35	3.78
Operating Income	-7.63	-4.35	-3.78
Other Non Operating Income (Expenses)	-0.58	-26	0
Pretax Income	-8.21	-30.36	-3.78
Net Income	-8.21	-30.36	-3.78
Net Income to Common	-8.21	-30.36	-3.78
Shares Outstanding (Basic)	44	34	11
Shares Outstanding (Diluted)	44	34	11
Shares Change (YoY)	307.12%	219.94%	-
EPS (Basic)	-0.19	-0.89	-0.35
EPS (Diluted)	-0.19	-0.89	-0.35
EBIT	-7.63	-4.35	-3.78

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q